Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer (Q33391448)

26 July 2017

1 reference

2 October 2019

1 reference

title

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer (English)

1 reference

local neoplasm recurrence

26 July 2017

main subject

1 reference

PubMed

lung small cell carcinoma

2 October 2019

1 reference

2 October 2019

1 reference

2 October 2019

1 reference

17 September 2019

topoisomerase inhibitor

1 reference

2 October 2019

5

Jos Kleijnen

1 reference

26 July 2017

1

Rob Riemsma

1 reference

26 July 2017

2

Jean P Simons

1 reference

26 July 2017

3

Zahid Bashir

1 reference

26 July 2017

4

Caroline L Gooch

1 reference

26 July 2017

language of work or name

English

0 references

publication date

17 August 2010

5 references

26 July 2017

28 February 2019

3 April 2019

17 September 2019

2 October 2019

5 references

26 July 2017

28 February 2019

3 April 2019

17 September 2019

2 October 2019

10

1 reference

26 July 2017

page(s)

436

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

copyright license

4 references

28 February 2019

3 April 2019

17 September 2019

on focus list of Wikimedia project

2 October 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Patient preferences for oral versus intravenous palliative chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931489

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-436

CELL TYPE AND THE NATURAL HISTORY OF LUNG CANCER

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20716361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Étude de phase 2, randomisée, évaluant une polychimiothérapie orale (CCNU, Cyclophosphamide, étoposide) et une polychimiothérapie intraveineuse dans les cancers bronchiques à petites cellules en seconde ligne en rechute (essai GFPC0501)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20716361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-10-436

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference